A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use

Vaccine

Volumn 28, Issue 1, 2009, Pages 14-20

  Wagner, K S ^a   Stickings, P ^b   White, J M ^a   Neal, S ^a   Crowcroft, N S ^a,c   Sesardic, D ^b   Efstratiou, A ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

Antitoxin; Diphtheria; Immunoglobulin

Indexed keywords

ANTIINFECTIVE AGENT; DIPHTHERIA ANTIBODY; DIPHTHERIA TOXIN;

CORYNEBACTERIUM DIPHTHERIAE; DIPHTHERIA; DISEASE SURVEILLANCE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MANUFACTURE; DRUG UTILIZATION; ENDEMIC DISEASE; HEALTH SURVEY; HUMAN; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECOMMENDED DRUG DOSE; REVIEW; SEROEPIDEMIOLOGY; UNSPECIFIED SIDE EFFECT; VACCINATION;

BIOLOGICAL PRODUCTS; DIPHTHERIA; DIPHTHERIA ANTITOXIN; HUMANS;

EID: 70649115360     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.094     Document Type: Review

References (55)

1. Begg N. Manual for the management and control of diphtheria in the European region. Expanded Programme on Immunization in the European Region of WHO; 1994.
2. De Zoysa A., Hawkey P.M., Engler K., George R., Mann G., Reilly W., et al. Characterization of toxigenic Corynebacterium ulcerans strains isolated from humans and domestic cats in the United Kingdom. J Clin Microbiol 43 9 (2005) 4377-4381
3. Lartigue M.F., Monnet X., Le Fleche A., Grimont P.A., Benet J.J., Durrbach A., et al. Corynebacterium ulcerans in an immunocompromised patient with diphtheria and her dog. J Clin Microbiol 43 2 (2005) 999-1001
4. Hatanaka A., Tsunoda A., Okamoto M., Ooe K., Nakamura A., Miyakoshi M., et al. Corynebacterium ulcerans diphtheria in Japan. Emerg Infect Dis 9 6 (2003) 752-753
5. Dorella F.A., Pacheco L.G.C., Oliveira S.C., Miyoshi A., and Azevedo V. Corynebacterium pseudotuberculosis: microbiology, biochemical properties, pathogenesis and molecular studies of virulence. Vet Res 37 2 (2006) 201-218
6. Uchida T., Gill D.M., and Pappenheimer Jr. A.M. Mutation in the structural gene for diphtheria toxin carried by temperate phage. Nat New Biol 233 35 (1971) 8-11
7. Seto Y., Komiya T., Iwaki M., Kohda T., Mukamoto M., Takahashi M., et al. Properties of corynephage attachment site and molecular epidemiology of Corynebacterium ulcerans isolated from humans and animals in Japan. Jpn J Infect Dis 61 2 (2008) 116-122
8. Pappenheimer Jr. A.M. Diphtheria toxin. Annu Rev Biochem 46 (1977) 69-94
9. Holmes R.K. Biology and molecular epidemiology of diphtheria toxin and the tox gene. J Infect Dis 181 Suppl 1 (2000) S156-S167
10. Iwamoto R., Higashiyama S., Mitamura T., Taniguchi N., Klagsbrun M., and Mekada E. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J 13 10 (1994) 2322-2330
11. Naglich J.G., Metherall J.E., Russell D.W., and Eidels L. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 69 6 (1992) 1051-1061
12. London E. Diphtheria toxin: membrane interaction and membrane translocation. Biochim Biophys Acta 1113 1 (1992) 25-51
13. Pappenheimer Jr. A.M. The diphtheria bacillus and its toxin: a model system. J Hyg (Lond) 93 3 (1984) 397-404
14. Sing A., Hogardt M., Bierschenk S., and Heesemann J. Detection of differences in the nucleotide and amino acid sequences of diphtheria toxin from Corynebacterium diphtheriae and Corynebacterium ulcerans causing extrapharyngeal infections. J Clin Microbiol 41 10 (2003) 4848-4851
15. World Health Organization. Diphtheria vaccine: WHO position paper. Weekly Epidem Rec 3 (2006) 24-32
16. Lucenko I., Perevoscikovs J., Kantsone L., Paberza R., Storozenko J., and Selga I. Diphtheria in Latvia 2002-2008: status and epidemiological trends [abstract A2.2]. Programme and abstracts of the second annual meeting of DIPNET & tenth international meeting of the European laboratory working group on diphtheria. Larnaca, Cyprus, November 5-7 (2008) 30
17. Tiwari T.S., Golaz A., Yu D.T., Ehresmann K.R., Jones T.F., Hill H.E., et al. Investigations of 2 cases of diphtheria-like illness due to toxigenic Corynebacterium ulcerans. Clin Infect Dis 46 3 (2008) 395-401
18. Schuhegger R., Kugler R., and Sing A. Pitfalls with diphtheria-like illness due to toxigenic Corynebacterium ulcerans. Clin Infect Dis 47 2 (2008) 288
19. A case of diphtheria caused by toxigenic Corynebacterium ulcerans. Commun Dis Rep CDR Wkly 2006;16(4).
20. http://nobelprize.org/nobel_prizes/medicine/laureates/1901/behring-lecture.html [Internet webpage, accessed 4 June 2009].
21. Logina I., and Donaghy M. Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 67 4 (1999) 433-438
22. Houdek J. The serum run of 1925. LitSite Alaska Digital Archives [article on the Internet, accessed 4 June 2009]. Available from: http://www.litsite.org/index.cfm?section=Digital-Archives&page=Land-Sea-Air&cat=Dog-Mushing&viewpost=2&ContentId=2559.
23. Brooks Tomblin B. The torch is lit. G.I. Nightingales: The army nurse corps in World War II (2003), University Press of Kentucky p. 67-94.
24. Simon J. The origin of the production of diphtheria antitoxin in France, between philanthropy and commerce. Dynamis 27 (2007) 63-82
25. Huntelmann A.C. Diphtheria serum and serotherapy. Development, production and regulation in fin de siecle Germany. Dynamis 27 (2007) 107-131
26. Friedland M.L. 1914 The Great War. The University of Toronto: a history (2002), University of Toronto Press p. 253-68
27. Bailey P. Henry Wellcome's Physiological and Chemical Research [article on the Internet, updated 2 December 2008; accessed 4 June 2009]. Available from: http://www.wellcome.ac.uk/About-us/History/WTX052313.htm.
28. Availability of diphtheria antitoxin through an investigational new drug protocol. Morb Mortal Wkly Rep 2004;53(19):413.
29. Wilde H., Thipkong P., Sitprija V., and Chaiyabutr N. Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis. Ann Intern Med 125 3 (1996) 233-236
30. Dittmann S., Wharton M., Vitek C., Ciotti M., Galazka A., Guichard S., et al. Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: lessons learned. J Infect Dis 181 Suppl 1 (2000) S10-S22
31. Niyazmatov B.I., Shefer A., Grabowsky M., and Vitek C.R. Diphtheria epidemic in the Republic of Uzbekistan, 1993-1996. J Infect Dis 181 Suppl 1 (2000) S104-S109
32. Galazka A.M., and Robertson S.E. Immunization against diphtheria with special emphasis on immunization of adults. Vaccine 14 9 (1996) 845-857
33. Galazka A. The changing epidemiology of diphtheria in the vaccine era. J Infect Dis 181 Suppl 1 (2000) S2-S9
34. Stark K., Barg J., Molz B., Vormwald A., and Bienzle U. Immunity against diphtheria in blood donors in East Berlin and West Berlin. Lancet 350 9082 (1997) 932
35. Souliou E., Kyriazopoulou V., Diza E., Hatzistylianou M., and Frantzidou F. Serological survey on the immunity to diphtheria of the northern Greek population. Eur J Epidemiol 13 5 (1997) 535-539
36. Edmunds W.J., Pebody R.G., Aggerback H., Baron S., Berbers G., Conyn-van Spaendonck M.A., et al. The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European Sero-Epidemiology Network. Epidemiol Infect 125 1 (2000) 113-125
37. Walory J., Grzesiowski J., and Hryniewicz W. The prevalence of diphtheria immunity in healthy population in Poland. Epidemiol Infect 126 2 (2001) 225-230
38. Volzke H., Kloker K.M., Kramer A., Guertler L., Doren M., Baumeister S.E., et al. Susceptibility to diphtheria in adults: prevalence and relationship to gender and social variables. Clin Microbiol Infect 12 10 (2006) 961-967
39. Yuan L., Lau W., Thipphawong J., Kasenda M., Xie F., and Bevilacqua J. Diphtheria and tetanus immunity among blood donors in Toronto. CMAJ 156 7 (1997) 985-990
40. Rasmussen I., Mengshoel A.T., Wallace S., Løvoll F.L., Nilsen Ø., Høiby E.A., et al. Outbreak of diphtheria in Oslo, Norway, May 2008 [abstract A2.5]. Programme and abstracts of the second annual meeting of DIPNET & tenth international meeting of the European laboratory working group on diphtheria. Larnaca, Cyprus, November 5-7 (2008) 33
41. Tiwari T, Clark T. Use of Diphtheria Antitoxin (DAT) for Suspected Diphtheria Cases. Investigational New Drug protocol published by the Centers for Disease Control and Prevention, Atlanta, GA [publication on the Internet, updated 30 April 2008; accessed 4 June 2009]. Available from: http://www.cdc.gov/vaccines/vpd-vac/diphtheria/dat/downloads/protocol_032504.pdf.
42. Sgouris J.T., Volk V.K., Angela F., Portwood L., and Gottshall R.Y. Studies on diphtheria immune globulin prepared from outdated human blood. Vox Sang 16 6 (1969) 491-495
43. Hartman L.J. Bioavailability study of diphtheria immunoglobulin (human). Pathology 11 3 (1979) 385-387
44. Galazka A. Implications of the diphtheria epidemic in the Former Soviet Union for immunization programs. J Infect Dis 181 Suppl 1 (2000) S244-S248
45. MacLennan J.M., Shackley F., Heath P.T., Deeks J.J., Flamank C., Herbert M., et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 283 21 (2000) 2795-2801
46. Health Protection Agency recommendation on the treatment and prophylaxis of tetanus [publication on the Internet, updated 21 April 2008; accessed 4 June 2009]. Available from: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1210060163478.
47. Bissumbhar B., Rakhmanova A.G., Berbers G.A., Iakolev A., Nosikova E., Melnick O., et al. Evaluation of diphtheria convalescent patients to serve as donors for the production of anti-diphtheria immunoglobulin preparations. Vaccine 22 15-16 (2004) 1886-1891
48. Provan D., Chapel H.M., Sewell W.A., and O'Shaughnessy D. Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. BMJ 337 (2008) a1831
49. Pelat T., Bedouelle H., Rees A.R., Crennell S.J., Lefranc M.P., and Thullier P. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 384 5 (2008) 1400-1407
50. Adekar S.P., Takahashi T., Jones R.M., Al Saleem F.H., Ancharski D.M., Root M.J., et al. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS ONE 3 8 (2008) e3023
51. Weiner L.M. Fully human therapeutic monoclonal antibodies. J Immunother 29 1 (2006) 1-9
52. Cha J.H., Brooke J.S., Chang M.Y., and Eidels L. Receptor-based antidote for diphtheria. Infect Immun 70 5 (2002) 2344-2350
53. Mitamura T., Higashiyama S., Taniguchi N., Klagsbrun M., and Mekada E. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 270 3 (1995) 1015-1019
54. Cooney D.O. Other biochemical and biological uses of charcoal. Activated charcoal in medical applications (1995), Marcel Dekker, New York p. 542-70
55. Mikhalovsky S.V., and Nikolaev V.G. Activated carbons as medical adsorbents. In: Bandosz T.J. (Ed). Activated carbon surfaces in environmental remediation (2006), Elsevier 529-561